Tecvayli access in India: the CDSCO Rule 36 named-patient pathway
How adults in India with relapsed or refractory multiple myeloma legally obtain Tecvayli (teclistamab-cqyv) from US-source supply, with REMS-equivalent CRS and ICANS readiness built into the case plan. This deep-dive extends the existing Tecvayli India access guide.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Tecvayli (teclistamab-cqyv) is the first BCMA x CD3 bispecific T-cell engager approved for multiple myeloma. The US Food and Drug Administration granted accelerated approval on 25 October 2022 for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. On 5 March 2026 the FDA converted the monotherapy approval to traditional (full) approval and, on the same date, approved teclistamab in combination with daratumumab and hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. The US supply runs through a restricted Risk Evaluation and Mitigation Strategy (REMS) channel because of the labeled cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) risks. Indian patients reach the medicine through the CDSCO personal importation framework under Rule 36 of the Drugs and Cosmetics Rules 1945, with Form 12A application and Form 12B permit issued by the Drugs Controller General of India (DCGI), or through the institutional Compassionate Use route at hospitals such as AIIMS New Delhi and Tata Memorial Centre Mumbai. Reserve Meds coordinates DSCSA-compliant US specialty-wholesaler sourcing through the REMS-certified channel, validated 2 to 8 degree Celsius cold-chain logistics, and the documentation kit your hematologist needs to file.
Reserved for you.
Why patients in India need Tecvayli via the named-patient pathway
India's hematology and bone-marrow-transplant capability is significant. Tata Memorial Centre Mumbai, AIIMS New Delhi, Christian Medical College (CMC) Vellore, PGIMER Chandigarh, Apollo Hospitals (Chennai flagship, Delhi, Bangalore, Hyderabad, Kolkata), Fortis Memorial Research Institute Gurgaon, Medanta The Medicity Gurgaon, Kokilaben Mumbai, MGM Chennai, and Manipal Hospitals Bangalore run BMT and complex hematology programmes. Proteasome inhibitors (bortezomib, carfilzomib), immunomodulatory agents (lenalidomide, pomalidomide), and anti-CD38 antibodies (daratumumab) are available locally. CAR-T capacity has grown, with NexCAR19 and other domestically developed cell therapies in clinical use. What is uniformly missing on local formularies for the triple-class-refractory patient is a BCMA x CD3 bispecific antibody as a routinely stocked product. Tecvayli is locally registered in some Reserve Meds markets but constrained by formulary listing, treatment-center accreditation for BCMA bispecific administration, or out-of-pocket affordability; in many Indian centres it is simply not on hand when the patient needs it. Reserve Meds maintains an existing Tecvayli India access guide that introduces the named-patient route at a higher level; this cell is the deep-dive companion.
The clinical case for reaching across the border is sequencing-driven. Tecvayli is positioned for patients who have progressed through triple-class therapy (PI plus IMiD plus anti-CD38) or, under the 2026 combination indication, after at least one prior line with daratumumab/hyaluronidase-fihj. It is also a key option for patients who have progressed after BCMA-directed CAR-T (Carvykti or Abecma) or who are ineligible for CAR-T because of disease tempo, organ function, or lack of access to a CAR-T capable centre. The Indian families who reach us at this point in the disease have typically been through multiple lines of myeloma therapy and need an off-the-shelf biologic with a defined step-up schedule and predictable manufacturing supply.
The CDSCO Rule 36 named-patient pathway for Tecvayli
The legal foundation for personal import of an unregistered or non-stocked medicine into India is Rule 36 of the Drugs and Cosmetics Rules 1945. Rule 36 permits the import of a small quantity of a drug, whose import would otherwise be prohibited under Section 10 of the Drugs and Cosmetics Act 1940, for the exclusive personal use of a named patient. Form 12A is the application for the permit. Form 12B is the permit itself, issued by the office of the DCGI at FDA Bhawan, Kotla Road, New Delhi, or by designated CDSCO Port Offices. The application is accompanied by a prescription from a Registered Medical Practitioner (RMP) showing the RMP's National Medical Commission (NMC) registration number and the quantity required for treatment. The quantity of any single drug imported is capped at one hundred average doses per application; for a weekly subcutaneous biologic this covers a meaningful treatment runway per filing.
For institutional Compassionate Use of drugs not approved or not locally stocked, the parallel pathway is the Compassionate Use application route to the DCGI by a government hospital, a registered medical practitioner, a pharmaceutical company, or the patient. Triple-class refractory multiple myeloma fits the life-threatening condition framing. AIIMS New Delhi, Tata Memorial Centre Mumbai, and CMC Vellore have established Compassionate Use workflow for advanced hematology.
For Tecvayli specifically, the clinical-justification angle in the Form 12A filing is the prior-line documentation, the CAR-T context where applicable, and the REMS-equivalent inpatient monitoring readiness. The strongest applications consistently document: a confirmed diagnosis of multiple myeloma with current International Staging System or Revised ISS stage, cytogenetics, and disease markers; for the monotherapy indication, the documented prior treatment sequence (at least four prior lines including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody), each with dates, regimen, response, and reason for discontinuation; for the combination indication (approved 5 March 2026), the documented prior line history (at least one prior line including a PI and an IMiD) with the proposed Tec-Dara combination regimen; the CAR-T context if relevant (prior progression after Carvykti or Abecma, or CAR-T ineligibility with the specific reason); the proposed dosing plan following the FDA-labeled monotherapy step-up schedule (Step-up Dose 1 Day 1 at 0.06 mg/kg, Step-up Dose 2 Day 4 at 0.3 mg/kg with 2 to 7 days separation, First Treatment Dose Day 7 at 1.5 mg/kg with 2 to 7 days separation, then 1.5 mg/kg weekly until progression; Q2W dosing available for patients who maintain a complete response or better for at least six months); the premedication plan (corticosteroid, antihistamine, antipyretic 1 to 3 hours prior to each step-up dose and the first treatment dose); and most critically the planned 48-hour inpatient observation after each of the three step-up doses and after the first full treatment dose, with documented CRS-response capacity (tocilizumab on hand, ICU escalation pathway) and ICANS-response plan. CDSCO's published guidance states Form 12B is typically issued within one to two business days for routine applications where documentation is complete; first-time BCMA-bispecific imports at an institution that has not previously administered Tecvayli may run longer for institutional pharmacy and clinical-readiness verification. Practical end-to-end planning runs two to four weeks from physician decision to dispensed material because upstream documentation assembly and downstream cold-chain logistics, not the regulator's stamp, set the pace.
Where Tecvayli gets dispensed in India
Tecvayli administration in India requires a tertiary or quaternary center with documented BCMA-bispecific or CAR-T-grade clinical readiness: an inpatient unit able to monitor patients for 48 hours after each step-up dose and after the first full dose, on-formulary tocilizumab and corticosteroid escalation pathway, ICU access, and a hematology service experienced with cytokine release syndrome and ICANS. The institutions that meet this profile in India most consistently are AIIMS New Delhi (NCI-designated cancer hub with comprehensive hematology and BMT), Tata Memorial Centre Mumbai (the country's flagship cancer institute with a 1,200+ patient myeloma cohort), Christian Medical College Vellore (long-running BMT and cellular therapy unit), PGIMER Chandigarh (north India referral hub), Apollo Hospitals' flagship sites in Chennai, Delhi, Bangalore, Hyderabad, and Kolkata, Fortis Memorial Research Institute Gurgaon (which administers domestic CAR-T), Medanta The Medicity Gurgaon, Kokilaben Dhirubhai Ambani Hospital Mumbai, MGM Healthcare Chennai, HCG Cancer Centre Bangalore, and Manipal Hospitals Bangalore.
The dispensing facility must hold a Drug License under the Drugs and Cosmetics Rules Schedule M and maintain validated 2 to 8 degree Celsius storage with continuous temperature monitoring. The chain-of-custody documentation runs from the US REMS-certified specialty wholesaler (typically McKesson Specialty, Cardinal Specialty, or Onco360 under Janssen's REMS contract) through the international cold-chain courier, through Indian customs at the relevant CDSCO Port Office, into the institutional pharmacy, and finally to the inpatient bedside at the time of each step-up administration. For physicians at smaller centers without internal import infrastructure, the common pattern is to route through a CDSCO-licensed pharmaceutical importer that holds the institutional relationship and files Form 12A on the prescribing physician's behalf.
Real cost picture for Tecvayli in India
US wholesale acquisition cost (WAC) for Tecvayli is approximately USD 25,000 per month for the standard 1.5 mg/kg weekly subcutaneous regimen at an average adult body weight, with the monthly figure scaling modestly with patient weight. Annual WAC at weekly dosing runs approximately USD 300,000 to USD 360,000 for an 80 kg adult. At the prevailing USD/INR rate (1 USD = approximately 83 INR in May 2026), monthly drug cost converts to roughly INR 20.7 lakh per month, or INR 2.5 to 3.0 crore per year at weekly dosing. Patients who maintain a complete response or better for at least six months and transition to Q2W dosing (approved 14 February 2024) effectively halve the ongoing monthly cost.
International cold-chain logistics from US specialty wholesaler to Indian institutional pharmacy typically runs USD 600 to USD 1,800 (approximately INR 50,000 to INR 1.5 lakh) per shipment depending on quantity, destination metro, and urgency. CDSCO Form 12A application fees are nominal relative to drug cost. The Reserve Meds concierge fee is a separate transparent line item on every firm quote. Patients moving from monotherapy to the new Tec-Dara combination indication (approved 5 March 2026) need to add daratumumab/hyaluronidase-fihj cost to the planning sheet; daratumumab subcutaneous is locally registered with CDSCO and is typically sourced through the standard institutional channel rather than as an import.
On the payer side, Indian private insurance behavior for triple-class-refractory myeloma is mixed. Star Health, HDFC ERGO, ICICI Lombard, Niva Bupa, and Tata AIG each assess BCMA-bispecific imports case by case; some reimburse a percentage subject to sub-limits and oncology riders, most require pre-authorization. CGHS provides for life-saving medicines not in the standard formulary to be considered case-by-case by an Expert Committee under Special DG (DGHS), with stricter constraints for drugs not approved by CDSCO. The National Policy for Rare Diseases 2021 financial assistance ceiling is below annual Tecvayli cost. Many myeloma-funded Tecvayli courses in India are paid by a mix of insurance, the patient's family across multiple cities, and overseas relatives wiring to a designated institutional account. We do not promise coverage from any insurer or scheme.
Typical timeline for Tecvayli in India
From the date a complete documentation set reaches Reserve Meds, the typical pattern is two to three weeks to first dose. CDSCO Form 12A filing to Form 12B issue runs one to two business days for routine applications and a few days longer for first-time BCMA-bispecific imports at the institution. US REMS specialty-wholesaler order placement and pick-pack-ship typically runs three to seven business days. International cold-chain transit to India runs three to six days door-to-door for major metro destinations. Customs clearance at the CDSCO Port Office runs one to three business days where documentation is in order. Institutional pharmacy receipt, quality verification, and scheduling of the first step-up dose runs two to four business days. The biological pacing is non-negotiable: Step-up Dose 1, Step-up Dose 2 (with 2 to 7 days separation), First Treatment Dose (with 2 to 7 days separation), then weekly 1.5 mg/kg until progression or transition to Q2W after six months of CR-or-better.
What your physician needs to provide
For an Indian hematologist or medical oncologist prescribing Tecvayli through the CDSCO Rule 36 pathway, the clinical justification letter is the cornerstone of the application. The letter, signed by a Registered Medical Practitioner holding an active National Medical Commission registration number, documents the patient's myeloma diagnosis with current ISS or R-ISS stage, cytogenetic risk markers (presence or absence of t(4;14), t(14;16), del(17p), 1q gain or amplification, TP53 mutation), serum free light chain ratio, M-protein trajectory, and bone marrow plasma cell percentage. The prior-therapy table covers each of the qualifying prior lines with regimen, dates, best response, duration of response, and reason for discontinuation. For the monotherapy indication this is at least four prior lines including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody; for the combination indication this is at least one prior line including a PI and an IMiD.
The dosing plan follows the FDA-labeled monotherapy step-up schedule (Step-up Dose 1 at 0.06 mg/kg, Step-up Dose 2 at 0.3 mg/kg with 2 to 7 days separation, First Treatment Dose at 1.5 mg/kg with 2 to 7 days separation, then 1.5 mg/kg weekly subcutaneous until progression; Q2W after six months CR-or-better) or the Tec-Dara combination schedule per the 5 March 2026 label. Premedication (corticosteroid, antihistamine, antipyretic 1 to 3 hours prior) is documented for each step-up dose and the first treatment dose. The monitoring plan covers the 48-hour inpatient observation after each step-up dose and after the first full treatment dose, CRS grading and tocilizumab readiness, ICANS monitoring with ICE score documentation, neutropenia and infection surveillance, hypogammaglobulinemia management with IVIG support, and ongoing pharmacovigilance reporting through the Indian Pharmacopoeia Commission's PvPI programme.
The treating physician's NMC registration number, the dispensing facility's Drug License number under Schedule M, and the institutional pharmacy in charge of receipt and dispensing complete the package. A CDSCO Form 12A application is filed online through the Sugam portal at cdscoonline.gov.in with the supporting documents uploaded.
Common questions about Tecvayli in India
Is Tecvayli registered in India? Tecvayli is not currently approved by CDSCO as a registered marketed product. Access for Indian patients runs through the Rule 36 personal-import pathway or institutional Compassionate Use. The Reserve Meds documentation kit prepares both the Form 12A application and the institutional Compassionate Use letter where the institution prefers that route.
Can my hematologist administer Tecvayli in India? Yes, at a center with documented BCMA-bispecific or CAR-T-grade readiness, on-formulary tocilizumab, ICU access, and an inpatient unit able to monitor 48 hours after each step-up and the first full dose. AIIMS, Tata Memorial, CMC Vellore, PGIMER, Apollo flagship sites, Fortis Memorial, Medanta, Kokilaben, MGM, HCG, and Manipal all meet this profile. Smaller centers route through one of the above for the step-up sequence and may transition the patient back for ongoing weekly administration.
Will Star Health, HDFC ERGO, ICICI Lombard, Niva Bupa, or Tata AIG cover this? Each insurer assesses BCMA-bispecific imports case by case. Some reimburse a percentage subject to oncology sub-limits; most require pre-authorization. Reserve Meds supplies the documentation set that lets an insurer assess; the claim itself sits with you or your hospital. Cash-pay is the default operating posture for cross-border named-patient supply.
How does Tecvayli compare to Carvykti for my disease state? Tecvayli is an off-the-shelf BCMA x CD3 bispecific antibody with a defined weekly subcutaneous schedule and a 48-hour inpatient observation requirement for each step-up dose. Carvykti is a BCMA-directed autologous CAR-T cell therapy delivered as a single infusion after lymphodepleting chemotherapy. Carvykti is a one-shot intervention with intensive upfront monitoring; Tecvayli is ongoing therapy with predictable manufacturing supply. Patients who progress on Carvykti or are CAR-T ineligible because of disease tempo, organ function, or center access frequently move to Tecvayli or talquetamab (Talvey, GPRC5D bispecific). The choice rests with the treating hematology team.
What is the inpatient observation requirement really like? The FDA label requires 48 hours of inpatient observation after each of the three step-up doses (Day 1, Day 4, Day 7) and after the first 1.5 mg/kg full treatment dose. Most Indian centers admit the patient for the step-up sequence as a single planned admission of approximately 8 to 12 days that covers all three step-up doses and the first full dose, then discharge with weekly outpatient administration thereafter. CRS, when it occurs, is typically Grade 1 to 2 and responds to acetaminophen and supportive care; Grade 3 or higher CRS is uncommon and managed with tocilizumab plus corticosteroid escalation.
What about ICANS? Immune effector cell-associated neurotoxicity syndrome is in the FDA label as a labeled risk. The Indian institutional pharmacy and clinical team monitor ICE score, hand-writing, level of consciousness, and language daily during the step-up window. ICANS is less common with bispecific antibodies than with BCMA CAR-T, but the readiness pathway (corticosteroid escalation, neurology consultation, ICU access) is the same. The patient and family receive a printed ICE-score sheet and a phone number to call between visits.
Can the medicine be given in a smaller city? The step-up sequence (Days 1, 4, 7 plus first full dose) is best done at a tertiary or quaternary center with the documented CRS and ICANS readiness above. After the step-up sequence and first treatment dose, weekly subcutaneous administration can be transitioned to a day-care oncology unit closer to home in coordination with the originating center. The cold-chain logistics and Form 12A documentation continue to route through the originating institution.
Where Reserve Meds fits in Tecvayli cases
Reserve Meds is a US-based concierge coordinator. We do not replace your hematologist, we do not replace CDSCO, and we do not replace your institutional pharmacy. For Tecvayli specifically, we orchestrate the US-side sourcing through a DSCSA-compliant REMS-certified specialty channel (Janssen contracts with McKesson Specialty, Cardinal Specialty, and Onco360), build the documentation kit your physician submits for Form 12A or institutional Compassionate Use, coordinate validated 2 to 8 degree Celsius cold-chain logistics with continuous temperature logging into India, assign a single named coordinator through the case, and stay through the multi-month weekly-dosing arc including refill cadence as the patient progresses to Q2W after six months of CR-or-better. Pediatric dosing does not apply: Tecvayli is adult-only.
Next step
If your hematologist has prescribed Tecvayli and you are weighing the cross-border route, the next step is a short waitlist request. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.